Drug Trial Radar · NCT04678453
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Jan 6, 2021
Primary completion
Aug 16, 2023
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- NKGen Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent, for the treatment of subjects with Alzheimer's disease.
Conditions
- Alzheimer Disease
- Neuro-Degenerative Disease
Interventions
SNK01Biological
Patient-specific ex vivo expanded autologous natural killer cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety profile of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.Time frame: Up to 6 months
- To determine the tolerability of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.Time frame: Up to 6 months
- To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of SNK01 monotherapy.Time frame: Up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Angeles Tijuana
Tijuana, Estado de Baja California, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.